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Abstract: We developed an agent-based stochastic model, based on P Systems methodology, to
decipher the effects of vaccination and contact tracing on the control of COVID-19 outbreak at
population level under different control measures (social distancing, mask wearing and hand hygiene)
and epidemiological scenarios. Our findings suggest that without the application of protection social
measures, 56.1% of the Spanish population would contract the disease with a mortality of 0.4%.
Assuming that 20% of the population was protected by vaccination by the end of the summer of
2021, it would be expected that 45% of the population would contract the disease and 0.3% of the
population would die. However, both of these percentages are significantly lower when social
measures were adopted, being the best results when social measures are in place and 40% of contacts
traced. Our model shows that if 40% of the population can be vaccinated, even without social control
measures, the percentage of people who die or recover from infection would fall from 0.41% and
56.1% to 0.16% and 33.5%, respectively compared with an unvaccinated population. When social
control measures were applied in concert with vaccination the percentage of people who die or
recover from infection diminishes until 0.10% and 14.5%, after vaccinating 40% of the population.
Vaccination alone can be crucial in controlling this disease, but it is necessary to vaccinate a significant
part of the population and to back this up with social control measures.
Keywords: control measures; vaccination; population dynamic P system; Spain
1. Introduction
A novel coronavirus (SARS-COV-2) spread quickly in China at the end of 2019, and
then rapidly in other areas. This new coronavirus causes a disease named COVID-19 whose
clinical expression varies widely between patients from an asymptomatic infection to a
severe disease requiring treatment in a hospital critical care unit. Many different symptoms
have been associated with this disease, varying from patient to patient. The most common
symptoms are cough, fever, shortness of breath or difficulty breathing, fatigue, muscle or
body aches, headache, loss of taste or smell, sore throat, and diarrhea [1–5]. A percentage of
patients eventually die as a consequence of the disease. Mortality rates vary by country as
well as by other factors including patient age, ethnicity, underlying diseases/co-morbidities,
and medical treatments applied [6].
The various waves of this viral pandemic have been difficult to control globally and
resulted in considerable fear within the populations affected as well as severe economic
impacts as governments and health authorities have struggled to devise effective control
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measures [7–10]. At the beginning of the outbreak, the control of the pandemic in Europe
was mainly based on strict social measures including social distancing and population
lockdowns [11–13]. While these have proved effective in the short term, they have high
economic costs as well as other consequences such as widespread mental health issues,
with unforeseeable impacts on society over the long run [14–16]. Social measures, based on
social distancing, strict hand hygiene, and the wearing of face masks have been proposed
as key measures to control this pandemic [17]. In some countries, it is compulsory to
always wear a face mask as a key measure to limit virus transmission and decrease the
reproduction ratio (R number) of the disease in the population [18,19].
Vaccination programs focused on limiting the transmission of infectious agents within
a population have provided considerable human health benefits [20,21]. Vaccination
reduces the susceptibility of an individual to infection as well as the chances of an infected
individual passing the infection to others. If enough people in a population achieve this
reduced susceptibility and infectivity, ‘herd immunity’ is said to have been achieved and
this certainly benefits a population greatly [22,23]. The chances of an individual becoming
infected decrease as the proportion of people vaccinated in a population rises, similar to
the situation in livestock diseases [24]. Pharmaceutical companies have made huge efforts
to develop vaccines against SARS-COV-2 to control the disease at the population level in
the shortest period of time. Many different approaches to developing efficacious vaccines
against SARS-COV-2 are in various stages of development [25] and currently three vaccines
are available and approved for use in the USA and Europe [26,27].
Mathematical models can provide new insights into the epidemiology of infectious
diseases and suggest criteria for the design of more efficient control strategies. Population
dynamic P system (PDP) models (inspired by the biology of cell function) provide an
alternative to traditional modeling for the study of complex problems [28]. They allow
handling of a very large number of interactions in a more efficient way [29,30] and have
not previously been applied in human epidemiology. A stochastic model based on PDP
modeling has been developed to study the course of COVID-19 epidemics under several
different epidemiological scenarios. This model [31] currently allows studying pandemic
dynamics in different interrelated geographical areas, and the effects of different control
measures in reducing the spread of the disease, e.g., polymerase chain reaction (PCR) tests
carried out by health personnel; vaccines; and administrative measures such as limiting
the number of people present at hospitality venues and meetings, the closure of communal
activities, the establishment of regional lockdowns, and other precautionary measures.
This paper sets out to disentangle the effects of vaccination and contact tracing to
control COVID-19 outbreak at population level where control measures (social distancing,
mask wearing and hand hygiene) are or not applied.
2. Materials and Methods
2.1. PDP COVID-19 Model
The PDP COVID-19 model described here is a PDP based stochastic model [31],
which allows the study of the course of a contagious disease outbreak under different
epidemiological scenarios. The complete model is included in the Supplementary Material
(Figures S1–S3, for details see [31]). The scenarios are described by values for the param-
eters of the model (Tables S1 and S2) that are usually inherent to the disease itself (e.g.,
probabilities of disease transmission, incubation time, and contagious period) and by the
measures applied in order to control it (e.g., population movement restrictions, wholesale
population testing, diagnosis, and vaccination). The time unit in the PDP COVID-19 model
is one day. The outcomes of the simulation are the number of people who died or who
recovered from infection (symptomatic plus asymptomatic). The sum of these two variables
estimates the number of infected people.
Our goals were to study and compare the effects of two control measures: vaccination
and contact tracing using diagnostic tests, with and without social control measures in
place. The social control measures considered are social distancing, hand hygiene, and
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consistent face mask wearing outside of the home. As previously published by our research
group, the probability of transmission of this virus, from infected to non-infected people,
is close to 10% if the virus is in free circulation [31]. Protection of 100% of the population
by vaccination will, at least in the short term, be difficult to achieve. This study models a
variety of more realistic scenarios, whereby 10%, 20%, 30% and 40% of the population are
vaccinated over the near future (during the year 2021). Those vaccinated were chosen at
random from the model population. While there are several different diagnostic tests, we
focused on the subsequent contact tracing and PCR test for all the contacts traced. Moreover,
all the persons who have had close contact with a COVID-positive person (contact tracing)
are identified and required to self-quarantine. Since it is difficult, if not impossible, to trace
100% of the contacts, the effects on the course of the pandemic of tracing 10%, 20%, 30%
and 40% of the contacts was studied. Because social control measures are simple and can
be applied simultaneously with other measures, such as contact tracing and population
vaccination, we ran two sets of models for the percentages of vaccination and or diagnostic
tests/contact tracing, with and without social control measures.
2.2. Statistical Study and Sensitivity Analysis
All statistical analyses were performed using the R Core package [32] (R Core 2018,
https://www.R-project.org/) (accessed on 15 September 2020). The COVID-19 PDP model
was used to execute two Box–Behnken designs, each with three factors at two levels and
two response variables. The response surface gives the mathematical relationship between
the independent variables and the response variables, using a quadratic model. This
surface was used to study the sensitivity of the PDP model to the values of the statistically
significant independent variables. The population modeled had no restrictions on normal
activities (work, schools, the use of restaurants and people movements). Each design
involved 16 sets of experiments. The factors in the first design were: the number of
people infected at time 0 (10,000 or 50,000); the percentage of the population protected
by vaccination (10% or 40%); and the probability of disease transmission from infected
to non-infected people (0.05 or 0.10). The factors in the second design were the same,
except for the percentage of people protected by vaccination (assuming non transmission
after vaccination), which altered according to the percentage of contacts with positives
traced (0% or 40%). The outcomes of the simulations were the number of people who died
and who recovered from infection (both symptomatic and asymptomatic). Four response
surfaces were obtained, one for each dependent variable.
2.3. Ethical Statement
Not necessary because of the entirely theoretical approach of this study.
3. Results
3.1. The Effects of Vaccination
3.1.1. Response Surface
A response surface was obtained for each response variable (Table 1). The probability
of disease transmission from infected to non-infected people (with or without social control
measures) and the proportion of the population protected by vaccination were statistically
significant for both the number of people who died or recovered from infection (p < 0.001).
There were no observed significant differences between the models starting the simulation
with 10,000 or 50,000 infected people. Therefore, the number of foci or people infected at
the time of vaccination is not significant, probably due to the rapid spread of the virus in
the population.
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Table 1. Box–Behnken estimated values of the response surface parameters. Disease control measures, and vaccine and
protection measures.
Parameter
Died R2 = 0.96 Recovered R2 = 0.97
Value (*) p-Value Value (*) p-Value
(Intercept) 118,259.5 <0.001 17,077,712 <0.001
Probability of disease transmission (Pd) 27,333.1 <0.001 4,390,755 <0.001
% of the population protected by vaccination (V) −37,108.5 <0.001 −4,674,854 <0.001
Number of people infected at time 0 (F) 5560.6 0.06991 −19,057 0.9136
Pd × V −3146.7 0.41215 −318,566 0.2296
Pd × F −1788 0.63444 64,945 0.7943
V × F 3927.8 0.31357 −13,346 0.9571
Pd2 −6782.2 0.1063 −915,654 0.0085
V2 3031 0.42859 −303,586 0.2497
F2 −3087.3 0.42054 331,471 0.2135
* The estimated values of the parameters are referred to the coded values, −1 and +1, of the factors (lower level and upper level).
Using the model, if 40% of the population was protected by vaccination, there were
74,217 (2 × 37,108.5, Table 1) fewer estimated deaths and 9 million fewer estimated infec-
tions (20% of the total population in Spain) compared with the simulation based on 10%
(low level of the experiment) of the population protected by vaccination. Moreover, if social
measures were applied in the population, there were 54,666 fewer estimated deaths and
8.8 million fewer estimated infections than when no social measures were applied using
the model.
3.1.2. Sensitivity Analysis
Using the surfaces obtained with the Box–Behnken design (Table 1), the sensitivity of
the model to small variations in the parameters was also estimated. Small variations (1%)
in the parameters (probability of disease transmission from infected to non-infected person
and the percentage of people protected by vaccination) had a great impact on the outcome
variables (dead or recovered people) (Table 2).
Table 2. Estimated sensitivity using response surfaces. Disease control measures: vaccine and protection measures affecting
the probability of disease transmission from infected to non-infected people.
Dead
people
Probability of disease transmission from
infected to non-infected people 10,933
People who die if the probability of transmission
of the disease is increased by 1%
Percentage of people protected
by vaccination −1855
Decrease in the number of people who died if the
number of vaccinated people is increased by 1%
Recovered
people
Probability of disease transmission from
infected to non-infected people 1,756,302
Number of people who recovered due to a 1%
increase in the probability of disease transmission.
Percentage of people protected
by vaccination −233,743
Number of people who recovered due to a 1%
increase in the population protected
by vaccination.
3.1.3. Vaccination Activity
The effect on the course of the pandemic due to different levels of the population
protected by vaccination was compared in a population with 30,000 infected people at time
0. The vaccine was administered at time 0 and the probability of disease transmission from
infected to non-infected people in the population was 0.05 or 0.1, when social measures
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were applied or not, respectively [30]. The population had no restrictions on normal
activities, such as work, schools, or the use of restaurants and bars.





VWV = Value obtained without vaccination
VAVp = Value when a proportion (p) o f the population was vaccinated
Table 3. Average number of expected people who died or recovered following infection depending
on the level of population protection provided by vaccination. Percentages are with respect to
population size (46,014,554 people).
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Population Protected by Vaccination (%)

































(Difference between the value without and with protection by vaccination).
The decreases observed, for any given probability of transmission without vaccina-
tion, were much greater when the probability of transmission was 0.05. The numbers of
people who died or recovered decreased significantly as the percentage of the population
protected by vaccination increased from 0% (control) to 40% (maximum level modeled,
for practical reasons) (Table 3 and Figure 1). This decrease was observed independently
of the probability of transmission. Moreover, as expected, reductions in the probability of
transmission (when social measures were applied) contributed significantly to reducing
the number of deceased and recovered people.
3.2. Tracing Activity
3.2.1. Response Surface
Table 4 shows the results for three response variables. The number of people dying
or recovering after infection, and the number of diagnostic tests to be performed, which
allow quantification of the resources necessary to carry out tracing as a control measure.
The probability of disease transmission and the percentage of people traced significantly
affect all the response variables (p < 0.05). The effect of the number of initial foci in the
range studied (10,000–50,000) is not statistically significant.
Following-up 40% of the positive contacts would reduce the number of people dying
to 122,192 and those who eventually recover to 10,746,450, but it would be necessary to
perform 40,528,888 diagnostic tests using a PDP model over an 80-day period. Reducing
the probability of disease transmission from 10% (without social measures) to 5% (with
social measures) plus applying contact tracing, would result in an additional reduction in
the number of people dying by 34,100 and those recovering by 7,321,524; and a reduction
in diagnostic tests to 10,956,670 using a PDP model over an 80-day period.
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Figure 1. Graphs (A,B) show the progress of the death toll in Spain depending on the percentage of the population protected
by vaccination (from 0% (V0) to 40% (V40)), with and without the application of social measures, respectively using a
population dynamic P system (PDP) model over an 80-day period. Graphs (C,D) show the number of people recovering
depending on the percentage of the population protected by vaccination (from 0% (V0) to 40% (V40)) with and without the
application of social measures, respectively using a PDP model over an 80-day period.











Value (*) p-Value Value (*) p-Value Value (*) p-Value
(Intercept) 48,039 <0.001 13,511,678 <0.001 27,364,890 <0.001
Probability of disease transmission (Pd) 17,049.88 <0.001 3,660,762 <0.001 5,478,335 <0.001
Percentage of people being traced (T) −61,096 <0.001 −5,373,225 <0.001 20,264,444 <0.001
Number of people infected at time 0 (F) 433.12 0.8205 −32,519 0.8367 −92,972 0.8493
Pd × T −14,757 0.0012 −1,025,858 0.0030 4,683,341 <0.001
Pd × F 195.25 0.9422 −365,194 0.1383 −811,020 0.2671
T × F −78 0.9769 −17,971 0.9357 24,372 0.9719
Pd2 −1053.62 0.6976 −590,357 0.0327 −954,013 0.2002
T2 43,716.62 <0.001 2,515,438 <0.001 −6,884,809 <0.001
F2 2329.38 0.402 88,975 0.692 522,739 0.460
* The estimated values of the parameters are referred to the coded values, −1 and +1 of the factors (lower level and upper level).
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3.2.2. Sensitivity Analysis
The sensitivity of the model to variations in the values of the parameters was tested us-
ing the response surfaces (Table 5). Reducing the probability of disease transmission from in-
fected to non-infected people by 1% resulted in a reduction of 6820 deaths, 1,464,305 people
recovered and more than two million diagnostic tests. An increase of 1% in the percent-
age of people traced reduced the numbers of deaths and recoveries by 3055 and 268,661,
respectively, but increased the number of diagnostic tests required by approximately one
million using a PDP model over an 80-day period.
Table 5. Estimated sensitivity using response surfaces. Disease control measures: tracing and social control measures.
Dead
people
Probability of disease transmission
from infected to non-infected people 6820
Increase in the number of people who died by increasing
the probability of disease transmission by 1%
Percentage of people being traced −3055 Decrease in the number of people who died by increasingtracing contacts by 1%
Recovered
people
Probability of disease transmission
from infected to non-infected people 1,464,305
Increase in the number of people who recovered due to a
1% increase in the probability of disease transmission.
Percentage of people being traced −268,661 Decrease in the number of people who recovered due to a1% increase in tracing contacts.
Diagnostic
tests
Probability of disease transmission
from infected to non-infected people 2,191,334
Increase in the number of tests by increasing the
probability of disease transmission by 1%
Percentage of people being traced 1,013,222 Increase in the number of tests by increasing the tracingcontacts by 1%
3.2.3. Effect of Tracing Measures
The effect of contact tracing (persons in contact with someone testing positive) was
studied by analyzing the percentages of the contacts. People who had been in contact
with someone testing positive were monitored and quarantined in order to avoid any
transmission of the disease. The effect of contact tracing 10%, 20%, 30% and 40% of the
contacts was modeled and the results compared with those where contacts were not traced
(Figure 2).
In the case where social measures were applied (where the probability of disease
transmission is 0.05), the results of contact tracing are significantly better (Table 6) than
when social measures were not applied (where the probability of disease transmission
was 0.1). Curiously, relatively small percentages of contact tracing provided important
improvements in the incidence of disease cases, but this improvement did not increase
linearly with the increase in the number of diagnostic tests performed. Therefore, if social
measures were applied (and the probability of disease transmission was 5%), screening
10% of the positive contacts reduced the number of deaths by 0.21%, and if 40% of positive
contacts were traced, the reduction was 0.27%, increasing the diagnostic tests administered
from 13,106,761 to 31,767,937. Reducing the contacts traced to 20%, reduced the number of
deaths by 0.25%, increasing the number of tests by 6.7 million. On the other hand, where
the probability of transmission was 0.1 (without social measures), the results were similar
to those where social measures were applied (with a probability of transmission of 0.05),
but more diagnostic tests were carried out (Table 7).
3.3. Analyzing Simultaneous Contact Tracing and Vaccine Protection
It is to be expected that only a small part of the worldwide population could be
vaccinated during 2021 due to vaccine availability and logistical issues. In the case of Spain,
twenty million vaccine doses, with an efficacy of around 90% for a recently authorized
mRNA vaccine [26], could be available by summer 2021 [33]. This would mean that only
19.6% of the Spanish population would be protected by vaccination by the summer of
2021 (each vaccinated person requires two doses). It is estimated that at least 60–80% of
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the population must be immune, either through vaccination or by natural infection, to
bring an end to the pandemic [34,35]. The immunity obtained by vaccination plus the
immunity from natural infection would be far below this value in Spain by summer 2021.
The combined effects of vaccination plus contact tracing must therefore be modeled to
discover the effects of both of these disease control measures. In a final simulation setting,
the percentage of the population protected by vaccination at 19.6%, the effect of tracing
10%, 20%, 30% and 40% of positive contacts was modeled in the case both of applied social
measures (with 5% probability of transmission) and without social measures (with 10%
probability of transmission).
Figure 2. Graphs (A,B) show the progress of the death toll in Spain depending on the percentage of contacts traced (from
0% (T0) to 40% (T40)) with and without the application of social measures, respectively using a PDP model over an 80-day
period. Graphs (C,D) show the number of people recovering depending on tracing contacts (from 0% (T0) to 40% (T40))
with and without the application of social measures, using a PDP model over an 80-day period. Graphs (E,F) show the
number of diagnostic tests carried out depending on tracing contacts (from 0% (T0) to 40% (T40)) with and without the
application of social measures, using a PDP model over an 80-day period.
If no social measures are applied to protect the population, it would be expected that
56.1% of the population would contract the disease and 0.4% of the population would die
from it, using our PDP model over an 80-day period (Table 8 and Figure 3). Moreover, if
19.56% of the Spanish population was protected by vaccination by the end of the summer of
2021, it would be expected that 45% of the population would contract the disease and 0.3%
of the population would die (Table 8 and Figure 3). However, both of these percentages are
always significantly lower if social measures were adopted. The best results were obtained
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with social measures in place and 40% of contacts traced (Table 8 and Figure 3). Finally, if
the percentage of contact tracing increases, both percentages decrease but the relationship
between these decreases and the number of tests carried out declines, so that increasing the
number of tests becomes relatively inefficient at tracing levels over 30% (Tables 8 and 9).
Table 6. Average number of expected people who died or recovered depending on the percentage of contact tracing carried
out in the population. Percentages are with respect to population size (46,014,554 people).
Social Measures
People with Positive Contacts That Have Been Traced (%)
0 10 20 30 40
With
(p = 0.05)
Died 0.33 0.12 (0.21) 0.08 (0.25) 0.06 (0.27) 0.06 (0.27)
Recovered 45.34 25.88% (19.46) 20.15 (25.19) 18.26 (27.08) 16.45 (28.89)
Without
(p = 0.1)
Died 0.41 0.21 (0.20) 0.14 (0.27) 0.10 (0.31) 0.07 (0.34)
Recovered 56.11 44.15 (11.96) 37.14 (18.97) 32.24 (23.87) 27.48 (28.63)
(Difference between the value without and with protection by vaccination).
























Table 8. Percentage of the total number of people who died or recovered depending on the percentage of contact tracing
carried out in the population if there 19.56% of the population are protected by vaccination.
Percentage of the Population No Vaccine
19.56% of the Population Protected by Vaccination
Positive Contact Tracing (%)
0 10 20 30 40
With social measures
(p = 0.05)
Died 0.17 0.09 0.06 0.06 0.05
Recovered 26.96 19.60 14.46 13.26 10.62
Without social measures
(p = 0.1)
Died 0.4 0.31 0.16 0.11 0.08 0.08
Recovered 56.1 45.06 36.06 30.37 26.83 28.68
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Figure 3. Graphs (A,B) show the progress of the death toll in Spain depending on the percentage of traced contacts (from
0% (T0) to 40% (T40)) without and with the application of social measures, with 19.6% of the population protected by
vaccination, using a PDP model over an 80-day period. Graphs (C,D) show the number of people recovering depending
on contact tracing (from 0% (T0) to 40% (T40)) without and with the application of social measures, with 19.6% of the
population protected by vaccination using a PDP model over an 80-day period. Graphs (E,F) show the number of diagnostic
tests carried out depending on contact tracing (from 0% (T0) to 40% (T40)) without and with the application of social
measures, with a 19.6% of the population protected by vaccination, using a PDP model over an 80-day period.
Table 9. Diagnostic tests performed as a percentage of the Spanish population (46,014,554) when vaccination protects 19.6%
of the population and contact tracing follows up 10% to 40% of contacts with an infected person.
Probability of Disease
Transmission














(p = 0.05) 19.3 (8,876,461) 27.7 (12,750,293) 36.8 (16,927,530) 39.0 (17,930,132)
Without social measures
p = 0.10 33.4 (15,346,800) 52.5 (24,166,442) 68.0 (31,294,462) 78.8 (36,247,483)
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4. Discussion
The strict social-distancing interventions in response to the COVID-19 pandemic
during the first quarter of 2020, appear to have successfully interrupted virus transmission
in many countries but this has been at the expense of huge societal disruption and economic
costs [36,37]. Several modeling studies have already pointed out that resuming normal
economic activities and social life would likely lead to a resurgence of the COVID-19
epidemic and this effect has been observed in many countries where restrictions were
relaxed after the summer of 2020 [18,38,39]. In the light of these experiences, it is vital that
policy-makers and governments identify strategies that allow economic and social activities
to resume while still protecting lives and healthcare systems. To this end, mathematical
models can provide new insights into the epidemiology of infectious diseases and the
criteria necessary to design more efficient control strategies [40–43]. In this study, we
developed models using population parameters taken as case study Spain, that is one of
the most severely affected countries by the pandemic [44] but with the possibility to be
applied this model on other countries only by modifying the basic parameters.
Traditionally, ordinary differential equations (ODE), partial derivative equations and
models based on stochastic processes have been used to model the dynamics of biological
systems [28]. Despite their important limitations, ODEs have probably been the most
widely used. They are models that deterministically describe random phenomena and
use mean values without taking variability into account. In the modeling of population
dynamics and epidemiological diseases there is an important randomness due mainly
to the spatial distribution and movement of individuals, difficult to introduce in models
based on differential equations. The estimation of the parameters in a model of differential
equations is not simple in addition to being sensitive to the initial conditions. ODE models
are continuous models, so there is the possibility of obtaining negative values at some
point, which is not correct when modeling epidemiological diseases, nor does it make
sense to give fractional results considering individuals suffering from a disease. Due to the
inherent limitations of ODE models, we have developed a probabilistic model, based on
PDP model methodology, to model the course of the COVID-19 epidemic under several
different epidemiological scenarios. This model works with individuals (agent-based
model) in which each person moves around and acts according to their own specific
rules and they are grouped into bigger groups as communities in order to mimic better
the dynamics of a human population. For this reason, it is extremely complicated to
make direct comparison with the results obtained by other epidemiological studies due to
differences in the methodology of simulation, demography and social relationship in the
population, among others.
We did not consider potential changes to the virus transmissibility due to environmen-
tal factors: in particular, seasonal drivers such as temperature and humidity. Moreover, our
models also did not consider possible reintroduction of SARS-CoV-2 into the population
by infected travellers from other countries [45]. However, as our results suggests, the effect
of the number of initial foci do not affect statistically the final result. As in any model, our
results are contingent on the assumptions described, which are more thoroughly discussed
by Colomer et al. (2021) [31], including the considerable uncertainties surrounding the
transmission of SARS-CoV-2 which are being updated almost daily [46–49]. While our
results probably do not agree exactly with reality, they do serve as useful comparisons of
the likely outcomes in the presence of various control measures. For this reason, we per-
formed extensive sensitivity analyses which show that the modeling results presented here
are robust within the plausible range of parameter values for the course of the COVID-19
pandemic in Spain. Our model predicts that 56.1% and 0.41% of the Spanish population
become infected or die from infection during an eighty-day period if no social measures
are applied to control the disease. Fortunately, this result cannot be checked against reality
because of the large number of continuing strict social control measures applied to control
the disease at the beginning of the pandemic in Spain. However, our description of a base-
line situation (without social control measures) is close to the values predicted in Boston,
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USA [39] using a different modeling approach, where 75% of the entire population became
infected in a ninety-day period. Curiously, the basic R number described by these authors
at epidemic peaks (R0 = 4) is very similar to the value used by Colomer et al., (2021) [31]
in their unmitigated scenario (R0 = 5). On the other hand, the predicted unmitigated
infection-fatality ratio was 0.63% in the UK [50], using a different modeling approach, and
was higher than the value predicted in our model (0.41%). In fact, large variations in this
parameter have been described in many studies, probably due to uncertainties in the key
parameters chosen to run the models [51,52]. In any case, the differences that we found in
the predicted numbers of people infected and dying in a baseline situation versus those
described above are reasonable taking into account the different populations and models
used to make these predictions that make direct comparisons between studies misleading.
Vaccination against SARS-COV-2 appears to be the most important measure to control
the COVID-19 pandemic in the long run. Fortunately, several vaccines have now received
approval for use as emergency measures [26,27] although it will take time before most of
the population can be protected by vaccination. Our results clearly show that if 40% of
the population can be vaccinated, even without social control measures, the percentage
of people who die or recover from infection would fall from 0.41% and 56.1% to 0.16%
and 33.5%, respectively compared with an unvaccinated population. Remarkably, if social
control measures were applied in concert with vaccination the percentage of people who
die or recover from infection would only be 0.10% and 14.5% after vaccinating 40% of
the population. While it is clear that vaccination alone can be crucial in controlling this
disease, it is necessary to vaccinate a significant part of the population and to back this up
with social control measures. It must be highlighted that our model takes into account the
percentage of the population protected by vaccination calculated according to the vaccine
efficacy and vaccination coverage. Fortunately, the efficacies of the mRNA-based vaccines
recently approved are very high (>95%) [26]. Vaccine coverage will be very similar to the
percentage of the population protected by vaccination but any predictions must be revised
on a case-by-case basis because other COVID-19 vaccines could have a lower efficacy than
that published for mRNA-based technology [27]. Combined interventions of different
degrees and intensity will therefore be necessary to substantially delay and mitigate the
epidemic until herd immunity is reached by natural infection and vaccine protection [53].
Our results clearly show that social control measures are key in controlling the spread
of COVID-19 in a population with a low level of vaccine protection, which will probably
be the case during 2021 due to a shortage of vaccine supplies. Our findings regarding the
importance of social measures to control the COVID-19 pandemic differ from earlier studies
on COVID-19 during the first half of 2020 [54]. More recently, a systematic review published
in December 2020 [54] suggests a significant benefit from the wearing of protective face
masks in COVID-19 disease control. Recent publications have claimed that the use of face
masks can reduce virus transmission by 80% [18,19]. In our model, we assumed that social
measures could reduce the probability of virus transmission from infected to non-infected
people by 50% because there was no information available on this matter when this study
was performed. Taking into account the extra information now available, our results
could be considered very conservative regarding the beneficial role of social measures in
controlling the disease.
In summary, our results clearly support the extremely important role of social mea-
sures in controlling the disease at the population level [51]. On the other hand, damage
has been done to society by the striking changes in people’s habits and way of life due to
the long duration of the strict restrictions imposed by governments to fight the COVID-19
pandemic. The severity of the social and economic disruptions arising from social measures
mean that they may not always be respected, especially in subpopulations not severely
affected by the disease. Consequently, it is highly recommended that governments im-
plement effective information campaigns on the importance of social measures. In the
light of our results, it is vital that policy-makers and governments center their efforts in
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implementing efficient social measures and increase as much as possible contact tracing
and speed up the vaccination process.
Our results clearly support the value of contact tracing as an effective tool in controlling
the course of the pandemic, in common with other published studies [39,55,56] even with
a low (40%), but realistic level of contact tracing. The problem with this measure is that it
requires a large number of tests with a high cost for governments. It is difficult to say which
of the two measures, contact tracing or social measures, is to be preferred because they
require different resources. Contact tracing has financial and human resource costs while
social measures require that the population conform to the measures recommended by
health and government agencies. Again, our results clearly show that if everybody adheres
to the prescribed social control measures, the probability of transmission is reduced and the
resources required for tracing and testing fall significantly. In this regard, Li et al. 2020 [57]
described how social measures have a synergistic effect with contact tracing in the control
of a COVID-19 pandemic. However, strategies based on testing, isolation and contact
tracing might be significantly hampered if numerous infections are imported by visitors
from other areas. Travel restrictions, visitor screening and quarantine may also be required
for those arriving from places where sustained local transmission rates are high [45,58,59].
In this sense, Spain is a country where the reintroductions of SARS-COV-2 viruses (with
new variants) is quite probable due to international mobility on behalf of the tourism.
Our model does not include this possibility because the main goal was to disentangle the
effects of vaccination and contact tracing to control COVID-19 outbreak at population level
where control measures (social distancing, mask wearing and hand hygiene) are or not in
operation. According to our main goal, the introduction of new viruses from other countries
would have added to the model an overwhelming complexity without answering the main
question. This point is even more challenging for the every-day changing limitations of
mobility between countries that makes the starting points in the model very speculative.
Fortunately, our model is flexible enough to study this possibility in future studies.
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